On CNBC's “Mad Money Lightning Round,” Jim Cramer said AbbVie Inc. (NYSE:ABBV) is doing “very, very well.” However, he added that Abbott Laboratories (NYSE:ABT) remains his favorite in the group right now.
AbbVie was founded in 2013 when it became a separate company from Abbott.
On Oct. 9, UBS analyst Navin Jacob maintained AbbVie with a Neutral and raised the price target from $185 to $195.
When asked about Oracle (NYSE:ORCL), he said, “I like the prospects. But you're in it for the data center, and the data center business is excellent.”
Oracle recently launched Oracle Health Clinical Data Exchange, a cloud-based solution that streamlines medical claims processing through secure, automated data exchange between healthcare providers and payers.
Core Scientific, Inc. (NASDAQ:CORZ) is a “mini-Palantir,” Cramer said. He recommended buying Palantir (NYSE:PLTR).
On Oct. 11, B. Riley Securities analyst Lucas Pipes maintained Core Scientific with a Buy and raised the price target from $13 to $14.
“I just don't want to go there. I know that it's a good company, but I just don't want to hurt anybody,” Cramer said when asked about Clover Health Investments, Corp. (NASDAQ:CLOV).
The company recent said the Centers for Medicare and Medicaid Services (CMS) increased the Star rating of its PPO Medicare Advantage plans to 4 Stars for 2025, affecting payments in 2026.
GXO Logistics (NYSE:GXO) is a “very valuable company,” the “Mad Money” host said. “Just hold on.”
GXO recently announced a new transport partnership with Matalan.
Cramer said he really likes Sweetgreen, Inc. (NYSE:SG), adding that it is “terrific.”
Sweetgreen will release financial results for the third quarter after the closing bell on Thursday, Nov. 7.
Price Action:
- Oracle shares gained 0.4% to settle at $174.77 on Wednesday.
- AbbVie shares fell 0.7% to close at $190.46.
- Core Scientific shares gained 2.2% to close at $13.25 on Wednesday.
- GXO Logistics shares gained 2.6% to settle at $62.95.
- Sweetgreen shares fell 0.7% to close at $37.94 on Wednesday.
Read Next:
Image: Shutterstock
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
